论文部分内容阅读
肺癌的发病率和死亡率已居我国恶性肿瘤的第一位。以表皮生长因子受体,酪氨酸激酶为靶点的酪氨酸激酶抑制剂(EGFR-TKI)治疗肺癌已广泛引起关注。但部分患者在服用EGFR-TKI初期即出现原发耐药,有些患者在服用EGFR-TKI一段时间后产生继发性耐药,本文综述EGFR-TKl分子耐药机制的研究现状,探讨EGFR-TKl分子耐药机制重要的临床意义。
The incidence of lung cancer and mortality has ranked first in China’s malignant tumors. The treatment of lung cancer with the tyrosine kinase inhibitor (EGFR-TKI) targeting epidermal growth factor receptor and tyrosine kinase has attracted wide attention. However, some patients have primary drug resistance after taking EGFR-TKI, and some patients develop secondary drug resistance after taking EGFR-TKI for a period of time. This review summarizes the research status of EGFR-TKl drug resistance mechanism and explores the role of EGFR-TKl Molecular resistance mechanism of important clinical significance.